Are psychedelics actually medicine?: The Story

The vote that sank a revolution

August 2024. The FDA rejected MDMA-assisted therapy for PTSD. Lykos Therapeutics — formerly MAPS, a nonprofit that spent $135 million and three decades getting MDMA through trials — watched its Phase 3 data sink. The advisory committee voted 9-2 against. They cited functional unblinding, therapist misconduct at two sites, and inadequate adverse-event tracking. The most promising psychiatric candidate in a generation failed not because it did not work but because the system could not figure out how to evaluate it.

Six months earlier, the mood had been euphoric. Psilocybin trials at Johns Hopkins and Imperial College London were producing results that looked like typos. Treatment-resistant depression patients — people who had failed four, five, six antidepressants — showed sustained remission after one or two supervised sessions. Effect sizes dwarfed SSRIs. Roland Griffiths, who ran the foundational trials before his death in 2023, described watching terminal cancer patients lose their fear of death in a four-hour session.

The rediscovery problem

The backstory makes the results stranger. Psilocybin is not new. Indigenous Mesoamerican communities used it in healing ceremonies for at least three thousand years. Ayahuasca has been central to Amazonian practice for millennia. The clinical world is not discovering these compounds — it is rediscovering them inside a regulatory apparatus requiring the ceremonial context to be stripped away.

Behind the FDA’s rejection sit millions of people with treatment-resistant conditions and a Schedule I lock between them and the most promising compounds in a generation — urgency that clinical advocates consider a moral crisis. But the advisory committee members who voted no had watched this movie before: the benzo crisis, the opioid catastrophe, dramatic early results that collapsed under real-world conditions. Those cautious researchers did not dispute the data. They disputed the inference. This time it’s different is, for prohibitionists, the most dangerous sentence in drug policy — the phrase that preceded every pharmaceutical disaster of the last thirty years. And watching all of it from a position so old that clinical trials are a blip, tradition holders whose lineages predate the FDA by three thousand years recognize something the clinical world is only beginning to suspect: the compound without the container may not be the medicine at all.

Oregon legalized supervised psilocybin in 2020. Colorado followed. Australia reclassified. The clinical train has left the station. Whether it carries the right cargo depends on which group you ask.

Psilocybin is the active compound in mushrooms that Indigenous Mesoamerican communities used in healing ceremonies for at least three thousand years. In clinical trials at Johns Hopkins and Imperial College London, it produced the most dramatic psychiatric results in a generation — treatment-resistant depression patients showing sustained remission after one or two supervised sessions, with effect sizes dwarfing conventional antidepressants. In August 2024, the FDA rejected MDMA-assisted therapy for PTSD, not because the compound did not work but because the system designed to evaluate it could not figure out how to evaluate it. Functional unblinding, therapist misconduct, and inadequate safety tracking sank a thirty-year, $135 million effort. Oregon legalized supervised psilocybin in 2020 and licensed facilitators with 120 hours of training. A barber in Oregon requires 1,350. The compound works. Whether the compound is the medicine, or whether the medicine is something larger that a clinical trial cannot hold, remains the question no camp can afford to get wrong.

Perspectives:
- Clinical advocates
- Cautious researchers
- Prohibitionists
- Tradition holders